October 31, 2019 07:26 AM EDTUpdated 07:38 AM
Deals
R&D

Astel­las re­joins the au­toim­mune an­ti­body craze with Pan­dion part­ner­ship

Jason Mast

Editor

Over a year ago, Astel­las CEO Ken­ji Ya­sukawa an­nounced a large R&D re­struc­ture: 600 cut jobs, mul­ti­ple re­search sub­sidiaries shut down, and a re­jig­gered …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump an­nounces picks for FDA, CDC; No­var­tis seeks bolt-on deals, rais­es guid­ance; RFK Jr., Elon Musk may find ...

For CDC, Trump picks Dave Wel­don, a for­mer con­gress­man who pushed for vac­cine in­jury claims

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Sanofi in­tro­duces new 340B pay­ment mod­el — re­port

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times